New PDE-4 classes inhibitors {2-[1-(3-ethoxy-4-methoxyphenyl)-2-(N,N-dimethylaminosulfonyl)ethyl]isoindolin-1-one, 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7 tetrafluoroisoindoline, 2-(2,6-dioxoethylpiperidin-3-yl)-4-aminophthalimide, 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline- 1,3-dione,... and their structure analogues), or SelCIDs:
United States Patent 6,011,050
Muller , et al. January 4, 2000
--------------------------------------------------------------------------------
Substituted phenethylsulfones and method of reducing TNF.alpha. levels
Abstract
Phenethylsulfones substituted in the position .alpha. to the phenyl group with a 1-oxoisoindoline or 1,3-dioxoisoindoline group reduce the levels of TNF.alpha. in a mammal. Typical embodiments are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline- 1,3-dione and 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindoline- 1,3-dione.
--------------------------------------------------------------------------------
Inventors: Muller; George W. (Bridgewater, NJ); Man; Hon-Wah (Neshanic Station, NJ)
Assignee: Celgene Corporation (Warren, NJ)
Appl. No.: 340617
Filed: June 29, 1999
6 months from application filed to issued patent. They do not waste time???
Miljenko |
